Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co LtdfiledCriticalSunshine Lake Pharma Co Ltd
Publication of AR094627A1publicationCriticalpatent/AR094627A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Formas cristalinas de derivados de dihidropirimidina y composiciones farmacéuticas que comprenden las formas cristalinas reveladas en la presente, que se pueden usar para prevenir, controlar, tratar o reducir la gravedad de una enfermedad viral en un paciente, en especial infección por hepatitis B o una enfermedad causada por infección por hepatitis B. Reivindicación 1: Una forma cristalina del compuesto de la fórmula (1), o un tautómero o una de sus combinaciones.Crystalline forms of dihydropyrimidine derivatives and pharmaceutical compositions comprising the crystalline forms disclosed herein, which can be used to prevent, control, treat or reduce the severity of a viral disease in a patient, especially hepatitis B infection or a disease. caused by hepatitis B infection. Claim 1: A crystalline form of the compound of the formula (1), or a tautomer or a combination thereof.
ARP130103466A2012-09-272013-09-26
CRYSTAL FORMS OF DIHYDROPIRIMIDINE DERIVATIVES
AR094627A1
(en)
Compounds derived from nucleosides substituted in 4’-azido, 3’-fluoro or their salts, as inhibitors of vhc rna replication; pharmaceutical composition that includes them; and its use for the treatment or prophylaxis of hepatitis C virus (vhc) infection.